Scancell Holdings plc

AIM:SCLP Stock Report

Market Cap: UK£130.1m

Scancell Holdings Valuation

Is SCLP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCLP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SCLP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SCLP's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCLP?

Key metric: As SCLP is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SCLP. This is calculated by dividing SCLP's market cap by their current book value.
What is SCLP's PB Ratio?
PB Ratio-37.1x
Book-UK£3.50m
Market CapUK£130.14m

Price to Book Ratio vs Peers

How does SCLP's PB Ratio compare to its peers?

The above table shows the PB ratio for SCLP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average38x
FARN Faron Pharmaceuticals Oy
130.1x17.3%UK£149.1m
BVXP Bioventix
16.3xn/aUK£195.7m
AVCT Avacta Group
3.7x-2.1%UK£179.3m
TRX Tissue Regenix Group
1.7x170.8%UK£40.6m
SCLP Scancell Holdings
n/a-22.4%UK£130.1m

Price-To-Book vs Peers: SCLP has negative equity and a Price-To-Book Ratio (-37.1x) compared to the peer average (38x).

Price to Book Ratio vs Industry

How does SCLP's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
SCLP is unprofitableIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: SCLP has negative equity and a Price-To-Book Ratio (-37.1x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is SCLP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCLP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-37.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SCLP's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCLP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.14
UK£0.25
+76.9%
15.4%UK£0.30UK£0.21n/a3
Nov ’25UK£0.13
UK£0.25
+85.2%
15.4%UK£0.30UK£0.21n/a3
Oct ’25UK£0.14
UK£0.25
+83.5%
15.4%UK£0.30UK£0.21n/a3
Sep ’25UK£0.17
UK£0.25
+44.0%
15.4%UK£0.30UK£0.21n/a3
Aug ’25UK£0.16
UK£0.25
+54.8%
15.4%UK£0.30UK£0.21n/a3
Jul ’25UK£0.11
UK£0.25
+121.7%
15.6%UK£0.30UK£0.21n/a3
Jun ’25UK£0.10
UK£0.25
+144.9%
15.5%UK£0.30UK£0.21n/a3
May ’25UK£0.092
UK£0.25
+167.4%
15.5%UK£0.30UK£0.21n/a3
Apr ’25UK£0.10
UK£0.25
+141.3%
15.5%UK£0.30UK£0.21n/a3
Mar ’25UK£0.10
UK£0.27
+153.3%
12.8%UK£0.30UK£0.23n/a2
Feb ’25UK£0.12
UK£0.27
+126.4%
12.8%UK£0.30UK£0.23n/a2
Nov ’24UK£0.12
UK£0.27
+114.9%
12.8%UK£0.30UK£0.23UK£0.132
Oct ’24UK£0.17
UK£0.27
+58.2%
13.2%UK£0.30UK£0.23UK£0.142
Sep ’24UK£0.10
UK£0.27
+166.0%
12.8%UK£0.30UK£0.23UK£0.172
Aug ’24UK£0.11
UK£0.27
+150.9%
12.8%UK£0.30UK£0.23UK£0.162
Jul ’24UK£0.13
UK£0.27
+100.8%
12.8%UK£0.30UK£0.23UK£0.112
Jun ’24UK£0.15
UK£0.27
+76.7%
13.2%UK£0.30UK£0.23UK£0.102
May ’24UK£0.16
UK£0.27
+69.3%
13.2%UK£0.30UK£0.23UK£0.0922
Apr ’24UK£0.16
UK£0.27
+65.6%
13.2%UK£0.30UK£0.23UK£0.102
Mar ’24UK£0.18
UK£0.27
+47.2%
13.2%UK£0.30UK£0.23UK£0.102
Feb ’24UK£0.20
UK£0.27
+31.2%
13.2%UK£0.30UK£0.23UK£0.122
Jan ’24UK£0.25
UK£0.25
-0.6%
5.7%UK£0.26UK£0.23UK£0.102
Dec ’23UK£0.23
UK£0.25
+9.3%
5.7%UK£0.26UK£0.23UK£0.112
Nov ’23UK£0.17
UK£0.25
+43.6%
5.7%UK£0.26UK£0.23UK£0.122

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%